Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.

Journal of the American Academy of Dermatology（2020）

引用 153|浏览33

暂无评分

摘要

The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate-to-severe AD.

查看译文

关键词

atopic dermatitis,biologic therapy,dupilumab,IL-4,IL-13,long-term,open label,monoclonal antibody,efficacy,quality of life,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要